ETF Holdings Breakdown of NTLA

NTLA institutional holdings

Date	ETF ISIN/Name	Num Shares	Book value
2025-09-26	IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc))	71,944	USD 1,173,407
2025-09-26	IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc)	52,909	USD 862,946
2025-09-26	IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc))	61,663	USD 1,005,724
2025-09-26	IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist))	61,663	USD 1,005,724
2025-09-26	IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc))	1,217	USD 19,849 -1.8%
Total =		249,396	USD 4,067,650

Book value of shares is calculated on the adjusted close price of each day (row).

News associated with NTLA

Intellia Therapeutics (NASDAQ:NTLA) Shares Gap Up After Insider Buying Activity

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) shares gapped up before the market opened on Monday following insider buying activity. The stock had previously closed at $10.52, but opened at $11.07. Intellia Therapeutics shares last traded at $11.34, with a volume of 1,615,773 shares trading hands. Specifically, Director William J. Chase purchased 100,000 shares […] - 2025-08-27 02:18:42

Mitsubishi UFJ Asset Management Co. Ltd. Boosts Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Mitsubishi UFJ Asset Management Co. Ltd. lifted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 24.1% in the 1st quarter, HoldingsChannel reports. The firm owned 21,458 shares of the company’s stock after buying an additional 4,165 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd.’s holdings in Intellia Therapeutics were worth […] - 2025-08-15 05:44:58

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Purchased by XTX Topco Ltd

XTX Topco Ltd boosted its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 84.2% in the 1st quarter, HoldingsChannel reports. The firm owned 80,897 shares of the company’s stock after purchasing an additional 36,989 shares during the period. XTX Topco Ltd’s holdings in Intellia Therapeutics were worth $575,000 at the end of the […] - 2025-08-07 04:58:54

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Average Rating of “Moderate Buy” from Analysts

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have earned an average recommendation of “Moderate Buy” from the twenty ratings firms that are covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, twelve have given a buy rating […] - 2025-07-24 05:11:08

Commit To Buy Intellia Therapeutics At $10, Earn 28.5% Using Options

Investors considering a purchase of Intellia Therapeutics Inc (Symbol: NTLA) stock, but tentative about paying the going market price of $13.21/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in - 2025-07-21 12:36:47

Alps Advisors Inc. Sells 5,030 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Alps Advisors Inc. trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.1% in the 1st quarter, Holdings Channel reports. The firm owned 77,328 shares of the company’s stock after selling 5,030 shares during the quarter. Alps Advisors Inc.’s holdings in Intellia Therapeutics were worth $550,000 at the end of […] - 2025-07-15 06:25:51

Wealth Enhancement Advisory Services LLC Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Wealth Enhancement Advisory Services LLC purchased a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 13,789 shares of the company’s stock, valued at approximately $98,000. Several other large investors also recently modified […] - 2025-07-11 04:16:51

Brokerages Set Intellia Therapeutics, Inc. (NASDAQ:NTLA) Price Target at $33.37

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty research firms that are covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, six have given a hold rating, twelve have assigned a buy rating and one has given […] - 2025-07-02 03:14:50

SG Americas Securities LLC Sells 3,401 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

SG Americas Securities LLC lessened its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 41,437 shares of the company’s stock after selling 3,401 shares during the quarter. SG Americas Securities LLC’s […] - 2025-06-27 04:21:01

Rhumbline Advisers Reduces Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Rhumbline Advisers trimmed its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 156,838 shares of the company’s stock after selling 9,410 shares during the quarter. Rhumbline Advisers’ holdings in […] - 2025-06-20 04:22:49

GAMMA Investing LLC Raises Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

GAMMA Investing LLC increased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 1,961.2% during the first quarter, Holdings Channel.com reports. The firm owned 7,544 shares of the company’s stock after acquiring an additional 7,178 shares during the quarter. GAMMA Investing LLC’s holdings in Intellia Therapeutics were worth $540,000 at the end of […] - 2025-06-19 04:08:57

Intellia Therapeutics (NASDAQ:NTLA) Earns Buy Rating from HC Wainwright

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report)‘s stock had its “buy” rating reissued by equities researchers at HC Wainwright in a research report issued to clients and investors on Monday,Benzinga reports. They presently have a $30.00 target price on the stock. HC Wainwright’s price target indicates a potential upside of 213.15% from the company’s current […] - 2025-06-18 02:22:53

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Given Average Recommendation of “Moderate Buy” by Brokerages

Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) has been given an average rating of “Moderate Buy” by the twenty-one ratings firms that are covering the stock, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, six have issued a hold rating, thirteen have issued a buy rating and one […] - 2025-06-04 04:52:47

Nuveen Asset Management LLC Sells 105,170 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Nuveen Asset Management LLC trimmed its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 28.7% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 260,697 shares of the company’s stock after selling 105,170 shares during the quarter. Nuveen Asset Management LLC’s […] - 2025-06-03 06:04:57

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Acquired by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 5.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 483,185 shares of the company’s […] - 2025-06-03 05:13:02

ProShare Advisors LLC Has $389,000 Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

ProShare Advisors LLC grew its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 38.0% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 33,404 shares of the company’s stock after acquiring an additional 9,196 shares during the period. ProShare Advisors LLC’s holdings in Intellia Therapeutics were worth $389,000 at the end […] - 2025-05-29 05:04:57

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Acquires 15,888 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.5% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 227,255 shares of the company’s stock after buying an additional 15,888 shares during the period. MIRAE […] - 2025-05-21 05:40:53

BNP Paribas Financial Markets Has $5.11 Million Stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

BNP Paribas Financial Markets increased its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 78.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 438,458 shares of the company’s stock after purchasing an additional 192,096 shares during […] - 2025-05-14 06:12:50

Guggenheim Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $45.00

Intellia Therapeutics (NASDAQ:NTLA – Get Free Report) had its price target cut by investment analysts at Guggenheim from $55.00 to $45.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. Guggenheim’s price target indicates a potential upside of 440.87% from the stock’s previous close. […] - 2025-05-14 02:56:48

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives $36.47 Consensus Target Price from Brokerages

Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Get Free Report) have received an average recommendation of “Moderate Buy” from the twenty-one research firms that are presently covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, thirteen have assigned a buy recommendation […] - 2025-05-13 02:44:49

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Stock Holdings Cut by Voya Investment Management LLC

Voya Investment Management LLC lessened its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 7.1% during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 28,829 shares of the company’s stock after selling 2,213 shares during the period. Voya Investment Management LLC’s holdings in Intellia […] - 2025-05-12 05:26:58

Citigroup Cuts Intellia Therapeutics (NASDAQ:NTLA) Price Target to $10.00

Intellia Therapeutics (NASDAQ:NTLA – Free Report) had its price objective reduced by Citigroup from $14.00 to $10.00 in a research note released on Friday,Benzinga reports. They currently have a neutral rating on the stock. A number of other equities analysts have also commented on the stock. Wedbush restated a “neutral” rating and issued a $10.00 […] - 2025-05-12 04:26:47

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Shares Sold by Mariner LLC

Mariner LLC decreased its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 14.4% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 14,820 shares of the company’s stock after selling 2,496 shares during the quarter. Mariner LLC’s holdings in Intellia Therapeutics were worth […] - 2025-05-08 04:38:44

Dimensional Fund Advisors LP Purchases 528,962 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Dimensional Fund Advisors LP increased its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 36.5% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,976,212 shares of the company’s stock after purchasing an additional 528,962 shares during the quarter. […] - 2025-05-07 05:26:54

MetLife Investment Management LLC Buys 3,491 Shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA)

MetLife Investment Management LLC boosted its stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 59,187 shares of the company’s stock after purchasing an additional 3,491 shares during the period. […] - 2025-05-05 05:22:56

Renaissance Technologies LLC Makes New $1.15 Million Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Renaissance Technologies LLC acquired a new position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 98,700 shares of the company’s stock, valued at approximately $1,151,000. Several other institutional investors have also recently […] - 2025-04-30 05:40:57

Marshall Wace LLP Makes New Investment in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Marshall Wace LLP purchased a new stake in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 95,339 shares of the company’s stock, valued at approximately $1,112,000. Several other large investors also recently made […] - 2025-04-30 04:59:02

Barclays PLC Has $3.63 Million Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Barclays PLC boosted its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 6.4% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 311,632 shares of the company’s stock after buying an additional 18,837 shares during the period. Barclays PLC owned approximately 0.31% […] - 2025-04-29 05:19:03

Sterling Capital Management LLC Raises Stock Holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Sterling Capital Management LLC lifted its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 866.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 3,198 shares of the company’s stock after acquiring an additional 2,867 shares […] - 2025-04-25 05:34:52

Wells Fargo & Company MN Increases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Wells Fargo & Company MN increased its stake in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 38.3% in the fourth quarter, HoldingsChannel reports. The firm owned 277,692 shares of the company’s stock after buying an additional 76,872 shares during the period. Wells Fargo & Company MN’s holdings in Intellia Therapeutics were worth […] - 2025-04-23 04:34:49

Back to Listing

Disclaimer